10x Genomics Settles Litigation with Bruker Corporation

10x Genomics ( (TXG) ) just unveiled an announcement.

On May 12, 2025, 10x Genomics, Inc. reached a settlement and licensing agreement with Bruker Corporation, resolving all global litigation and proceedings between the parties. This agreement follows a series of lawsuits initiated by 10x Genomics against NanoString Technologies, Inc., which were inherited by Bruker after acquiring certain NanoString assets in May 2024, and is expected to lead to the dismissal of all claims within five days of the agreement date.

The most recent analyst rating on (TXG) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on 10x Genomics stock, see the TXG Stock Forecast page.

Spark’s Take on TXG Stock

According to Spark, TipRanks’ AI Analyst, TXG is a Neutral.

10x Genomics faces significant challenges with negative profitability and declining instrument revenue, indicating financial and operational pressures. Strong gross margins and cash flow improvements offer some stability, but valuation concerns and mixed earnings guidance contribute to a cautious outlook. The strategic workforce reduction and uncertain funding environment further dampen investor confidence.

To see Spark’s full report on TXG stock, click here.

More about 10x Genomics

10x Genomics, Inc. operates in the biotechnology industry, focusing on developing advanced genomic analysis tools and technologies.

Average Trading Volume: 3,594,443

Technical Sentiment Signal: Sell

Current Market Cap: $1.18B

For a thorough assessment of TXG stock, go to TipRanks’ Stock Analysis page.